Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

PURPOSE: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. Prexasertib (LY2606368) is a CHK1 small molecule inhibitor under clinical evaluation in multiple adult and pedi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Lowery, Caitlin D., Dowless, Michele, Renschler, Matthew, Blosser, Wayne, VanWye, Alle B., Stephens, Jennifer R., Iversen, Philip W., Lin, Aimee Bence, Beckmann, Richard P., Krytska, Kateryna, Cole, Kristina A., Maris, John M., Hawkins, Douglas S., Rubin, Brian P., Kurmasheva, Raushan T., Houghton, Peter J., Gorlick, Richard, Kolb, E. Anders, Kang, Min H., Reynolds, C. Patrick, Erickson, Stephen W., Teicher, Beverly A., Smith, Malcolm A., Stancato, Louis F.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2018
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445779/
https://ncbi.nlm.nih.gov/pubmed/30563935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2728
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन